GET DAILY SIGNALSImmunovant (IMVT) Shares Rise +24% on Positive IMVT-1402 Data
Key Takeaways
- Immunovant shares climbed roughly 24% over the last 30 days, rebounding from a closing price near $28.71 in mid-October to the mid-$35 range in recent trading.
- The rally was driven primarily by positive IMVT-1402 data in difficult-to-treat rheumatoid arthritis (D2T RA), reported alongside fiscal Q2 2027 results.
- The 600 mg dose met the trial's primary endpoint, while a narrower-than-expected quarterly loss reinforced investor enthusiasm.
- Several analysts raised their price targets following the update, though the stock remains below its mid-August 2026 peak near $45.
- Immunovant is a clinical-stage company with no approved products, so pipeline execution and upcoming FDA discussions remain the key swing factors.
- For more detail on valuation and catalysts, explore Immunovant's Price Targets, Earnings, and Forecast pages.
- Consider monitoring Trending AI Robots for automated, data-driven perspectives on this and other tickers.
Company Overview and Pipeline Focus
Immunovant, Inc. is a clinical-stage immunology company based in Durham, North Carolina, and a majority-owned subsidiary of Roivant Sciences (ROIV). The company is developing IMVT-1402 (imeroprubart), a fully human monoclonal antibody that targets the neonatal Fc receptor (FcRn) to lower circulating immunoglobulin G (IgG) autoantibodies, which drive many autoimmune conditions.
IMVT-1402 is being studied across several indications, including Graves' disease, difficult-to-treat rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and Sjögren's disease. Because Immunovant has no approved products and no product revenue, investors follow the stock primarily for clinical data readouts, regulatory progress, and the company's ability to fund development through potential commercialization. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Stock Performance Over the Past 30 Days and Quarter
Over the last 30 days, IMVT advanced approximately 24%, rising from a closing price of $28.71 on October 13 to the mid-$35 range in recent sessions, with the stock reaching an intraday high above $37 earlier in November. The move was concentrated in a sharp rally that followed the company's November 9 clinical and financial update.
The longer quarterly picture is more mixed. After trading near $45 in mid-August, shares declined steadily through September and October, touching a low around $26.73 on October 16. Even after the November rebound, the stock remains down roughly 15% from its mid-August levels, illustrating how quickly sentiment has shifted between pipeline setbacks and positive readouts. From what I see, this volatility is typical for clinical-stage names like this.
Key Catalyst Behind the Recent Rally
The primary catalyst was Immunovant's November 9, 2026 announcement that IMVT-1402 met its primary endpoint in the randomized-withdrawal portion of a potentially registrational trial in difficult-to-treat rheumatoid arthritis. The 600 mg dose achieved a 92.5% ACR20 response rate at Week 28 versus 75.6% for placebo (p=0.0139), while the 300 mg dose did not separate from placebo. The company said it plans to begin FDA discussions later in the year to define a registrational path forward.
The update arrived alongside fiscal second-quarter 2027 results, in which Immunovant reported an adjusted net loss of $0.47 per share, narrower than the roughly $0.74 loss analysts had expected. The company ended the quarter with $722.3 million in cash and cash equivalents, which management said provides runway through the potential commercial launch of IMVT-1402 in Graves' disease.
Analyst reactions reinforced the move. Wells Fargo raised its price target to $47 from $45 with an Overweight rating, Bank of America raised its target to $46 from $45 with a Buy rating, and Truist raised its target to $33 from $30 while maintaining a Hold rating. Shares jumped about 15% on the day of the announcement. I’m watching this closely as the data continues to evolve.
Factors Behind the Quarterly Decline
The quarterly decline before November's rebound stemmed largely from a pipeline setback. On September 23, 2026, Immunovant reported that a 57-patient proof-of-concept study of IMVT-1402 in cutaneous lupus erythematosus (CLE) did not meet its primary endpoint on the CLASI-A score at Week 12, prompting the company to discontinue development in that indication. The news pressured the stock through September and October.
The broader multi-month trend also reflects a strategic narrowing of the pipeline. Earlier in fiscal 2026, Immunovant discontinued its first-generation FcRn inhibitor, batoclimab, after Phase 3 studies in thyroid eye disease missed their primary endpoints, redirecting resources toward IMVT-1402. The CLE readout further concentrated investor attention on the rheumatoid arthritis, Graves' disease, and myasthenia gravis programs that now anchor the investment case.
Upcoming Catalysts and What to Monitor
Looking ahead, the most important near-term variable is the outcome of Immunovant's FDA discussions on a registrational path for IMVT-1402 in difficult-to-treat rheumatoid arthritis, which management expects to complete later this year or early next year. Topline data from potentially registrational studies in Graves' disease and myasthenia gravis are anticipated in calendar 2027, with chronic inflammatory demyelinating polyneuropathy data expected in 2028.
Investors are also likely to monitor spending and cash consumption, competitive developments in the FcRn inhibitor class, and any updates on trial design and timing. As a pre-revenue biotech, Immunovant remains highly sensitive to clinical outcomes and regulatory feedback, and future data readouts will be central to how the stock is valued. One thing that stands out is how execution on these programs could shape the next leg of the move.
Exploring AI-Driven Trading Perspectives
I often review Tickeron’s AI Trading Bots to get additional data-driven views on names like this one. These tools scan a wide range of tickers and strategies, allowing me to cross-check traditional analysis with automated signals without replacing my own research process. It helps keep the perspective balanced when volatility is high.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
IMVT in upward trend: price rose above 50-day moving average on November 09, 2026
IMVT moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend. In 30 of 36 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on IMVT as a result. In 77 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for IMVT just turned positive on October 22, 2026. Looking at past instances where IMVT's MACD turned positive, the stock continued to rise in 34 of 44 cases over the following month. The odds of a continued upward trend are 77%.
Following a +5.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMVT advanced for three days, in 203 of 265 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMVT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
IMVT broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for IMVT entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.575) is normal, around the industry mean (3.498). P/E Ratio (-10.865) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. IMVT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 48 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases.
Industry Biotechnology
Advertisement